Item 1(a). | Name of Issuer: |
Urovant Sciences Ltd. (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
Suite 1, 3rd Floor,11-12 St. James’s Square, London SW1Y 4LB, United Kingdom
Item 2(a). | Names of Persons Filing: |
The names of the persons filing this report (collectively, the “Reporting Persons”) are:
Perceptive Advisors LLC (“Perceptive Advisors”)
Joseph Edelman (“Mr. Edelman”)
Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor
New York, NY 10003
Perceptive Advisors is a Delaware limited liability company
Mr. Edelman is a United States citizen
The Master Fund is a Cayman Islands corporation
Item 2(d). | Title of Class of Securities: |
Common Shares, par value $0.000037453 (“Common Shares”)
G9381B 108
Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 30,330,432 outstanding Common Shares as of June 13, 2019 as reported in the Issuer’s Form10-K filed on June 14, 2019.
The Master Fund directly holds 1,598,277 Common Shares. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own the securities directly held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the securities directly held by the Master Fund.